---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124545"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:41:32.106729+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Syndax reports positive pivotal Phase 2 results for revumenib in R/R mNPM1 AML; CR/CRh 23%

## Summary
- Primary endpoint met: CR/CRh rate 23% (15/64; 95% CI 14%–36%; p=0.0014) in efficacy-evaluable adult patients.
- ORR 47% (30/64); 75% had prior venetoclax; 36% received ≥3 prior lines of therapy.
- Safety profile consistent; 5% discontinued due to TRAEs. Grade ≥3 TRAEs: QTc prolongation 21%, anemia 14%, febrile neutropenia 13%, DS 13%, platelet count decreased 11%.
- sNDA filing for R/R mNPM1 AML expected in 1H25; FDA decision on KMT2Ar acute leukemias expected in 4Q24.

## SEC filing metadata
- accession: 0000950170-24-124545
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017024124545/0000950170-24-124545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017024124545/sndx-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124545
- JSON: https://secwatch.observer/filing/0000950170-24-124545.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124545.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.